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(3-chain enhancer
(Ets/core-binding factor/T-cell activation)
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ABSTRACT The activity of the T-cell receptor 3-chain
gene enhancer is increased by activators of the protein kinase
C pathway during T-celI activation. Analysis of mutant en-
hancer constructs identified two elements, BE2 and 13E3,
conferring phorbol ester inducibility. Multimerized 13E2 acted
in isolation as a phorbol ester-responsive element. Both 13E2
and jPE3, which contain a consensus Ets-binding site, were
shown to bind directly to the product of the c-ets1 protoon-
cogene. Both regions also bound a second factor, core-binding
factor. Mutation of the 13E2 Ets site abolished the inducibility
of the 13E2 multimer. f3E2 and 13E3 Ets site mutations also
profoundly affected activity and inducibility ofthe enhancer. In
contrast, enhancer activity but not its inducibility was affected
by mutation ofthe 13E2 core-binding factor site. Cotransfection
studies showed that Ets-1 specifically repressed activity of the
multimerized 13E2 element and the complete T-cell receptor
13-chain enhancer. These data show that the T-cell receptor
13-chain enhancer responds to protein kinase C-mediated ac-
tivation signals via a functional domain, composed of two
elements, which contains binding sites for Ets transcription
factors and which is negatively regulated by Ets-l.
The af3 T-cell receptor, expressed by most T cells, is encoded
by genes that rearrange during thymocyte development (1, 2).
The T-cell receptor p-chain (TCR/3) locus initiates recombi-
nation at around day 14 in murine fetal thymic ontogeny, and
the a locus rearranges at about embryonic day 17 (3-5). The
a8 TCR is first expressed at the thymocyte cell surface on
embryonic day 18 at a low level together with CD4 and CD8
antigens (6). An increase in the surface level of the af3 TCR
on the CD4 and CD8 double-positive thymocyte population
has been observed and correlated with positive selection (7).
TCR gene expression is further regulated in mature T cells,
where antigen stimulation leads to an increase in transcrip-
tion of TCR a and f3 genes (8). Thus, TCR gene expression
is modulated both during thymic development and in mature
T cells.
The transcription of the TCRP gene is regulated by an
enhancer of -350 base pairs (bp), located 6 kilobases (kb) 3'
to the TCR/3 constant region locus, C/32 (9-12). This en-
hancer has been shown to be highly inducible by phorbol
esters, which mimic the immune activation and differentia-
tion of T cells (12).
We define two elements within the human TCR,8 enhancer
that confer phorbol ester inducibility and show that these
elements bind factors belonging to the Ets family of tran-
scription factors. The Ets-binding sites are adjacent to a
conserved "core" site found also in the enhancers from the
TCR y- and S-chain genes, the CD3 8- and E-chain enhancers,
the polyoma virus enhancer, and the enhancers of mamma-
lian C-type retroviruses (13-18). The core site in the mam-
malian C-type retroviral enhancers has been shown to be an
important determinant of the T-cell disease specificity of the
Moloney murine leukemia virus (19) and the leukemogenicity
of the SL3-3 munne leukemia virus (20).
METHODS AND MATERIALS
Cells. Cell lines were cultured in RPMI 1640 medium/10%o
fetal calf serum. The cell lines used were J6, a subline of the
human T-ALL cell line Jurkat, and K-562, an erythroleuke-
mic line.
Plasmids. The plasmid KS7.8 containing the TCRY3 en-
hancer was derived as described (12). Deletions were created
by oligonucleotide-directed mutagenesis. The oligonucleo-





AGGGTCT. The construct (E2x4 was produced by concat-
enating the double-stranded oligonucleotide 1E2 and cloning
into pBLCAT2. The sequence of the coding strand of PE2
was GATCCACAACAGGATGTGGTTTGACATTTA.
The mutant construct ,BE2M1x4 was prepared by using the
oligonucleotide GATCCACAACATTATGTGGTTTGA-
CATTTA. The plasmid pRSV-luciferase was used as an
internal standard for transfection efficiency (21). The 1.4-kb
chicken ets-1 clone (22) was ligated into the Xba I site of
expression plasmid pEF-BOS (23).
Chloramphenicol Acetyltransferase (CAT) Assays. Cells
were transfected using DEAE-dextran as described (12).
Induction with phorbol 12-myristate 13-acetate (PMA) was
achieved by dividing cells into two and incubating one
portion in medium containing PMA at 10 ng/ml. CAT assays
were done with the method of Sleigh (24).
Gel-Retardation Assays. Complementary oligonucleotides
were hybridized to create double-stranded probes and were
radioactively labeled by filling in single-stranded ends by
using avian myeloblastosis virus reverse transcriptase. Gel-
retardation assays were done with 1 ng (104-2 x 104 dpm) of
probe and -0.25 jug of insect cell extract containing recom-
binant Ets-1 (22) or 3 ,ul of purified core-binding factor (CBF)
protein (25). Complexes were electrophoresed on 4% poly-
acrylamide gels in 0.5x TBE (lx TBE is 90 mM Tris/64.6
mM boric acid/2.5 mM EDTA, pH 8.3). Gels were dried and
autoradiographed at -700C on Kodak XAR-5 film. The
Abbreviations: TCR8, T-cell receptor P chain; PMA, phorbol 12-
myristate 13-acetate; CBF, core-binding factor; HTLV-1, human
T-lymphotropic virus type 1; CAT, chloramphenicol acetyltrans-
ferase.
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GCACCCA; HTLV-1, CCCATTTCCTCCCCATGTT; and
HTLV-1M, CCCATTTGGTCCCCATGTT.
RESULTS
Two Phorbol Ester Response Elements Lie Within the TCRI8
Enhancer. The human TCRI3 enhancer used in these studies
was a 362-bp fragment. DNase I footprint analysis revealed
four clear areas of protection by nuclear extracts of the
human T-cell line Jurkat, designated PE1-j3E4 (data not
shown). These regions correspond broadly to those defined
by Gottschalk and Leiden (10).
To assess whether the human TCRB enhancer was induc-
ible under conditions of T-cell activation, transient transfec-
tions using Jurkat cells were done with a CAT reporter gene
under control of the herpes simplex virus thymidine kinase
(tk) promoter and the TCR/3 enhancer. Phorbol ester treat-
ment of Jurkat cells resulted in an induction of the activity of
the TCR/3 enhancer construct by at least 10-fold (Table 1,
KS7.8). To define the basis for this inducibility, each foot-
printing region was deleted, and the effect of the deletion on
phorbol ester inducibility and basal activity of the enhancer
was assayed (Table 1). Although the deletion of each foot-
printing region decreased activity of the enhancer, only
deletion of 83E2 and ,BE3 affected inducibility. Thus, deletion
of 83E2 reduced enhancer activity by at least 80% and
completely abolished phorbol ester inducibility, and deletion
of.3E3 moderately impaired inducibility. These results show
that f3E2 and ,BE3 are responsible for phorbol ester induc-
ibility of the TCR43 enhancer with ,BE2 apparently exerting
the major effect.
1SE2 Acts in Isolation as a Phorbol Ester-Responsive Ele-
ment. Four copies of fSE2 were placed upstream of the tk
promoter, and the activity of this construct (f3E2x4) in Jurkat
cells was measured. Table 2 shows that B3E2x4 construct
failed to enhance the promoter activity, in contrast with the
TCR8 enhancer (KS7.8) but was functional on induction with
PMA. This result showed that ,BE2 could function as a
phorbol ester-responsive element without the requirement
for interaction with other elements of the core enhancer. The
behavior of the fE2x4 construct in the B-cell line Daudi was
similar to that in Jurkat cells, being functional only upon
PMA induction (data not shown).
Multimerized PE2 was also inducible in the erythroleuke-
mic cell line K-562, although in this cell line the element was
a potent transcriptional enhancer ofthe CAT reporter gene in
the absence of PMA. The TCR# enhancer also functioned
well in K-562 cells and was inducible with PMA (Table 2).
.8E2 and I3E3 Contain an Ets-Binding Site. Comparison of
the sequences of the ,BE2 and (3E3 regions reveals several
notable features (Fig. 1). (i) They are inverted repeats,
sharing two areas of sequence homology; (ii) they contain
sequences that correspond to motifs within other enhancers.
Table 1. Basal and inducible activity of deletion mutants of the
TCR,8 enhancer






*Activity in cpm x 1O-3, normalized for luciferase activity.
tRatio of + PMA to - PMA.




Construct - PMA + PMA - PMA + PMA
KS7.8 15 147 39 107
,BE2x4 0 43 42 135
*Activity in cpm x 10-3, normalized for luciferase activity.
One motif (Fig. 1, underlined) is related to the purine-rich
Ets-binding sites in several viral and cellular promoter/
enhancer sequences and to the recently defined consensus-
binding site for Ets-1 (refs. 26 and 27). /3E2 and f3E3 also
contain a second region of homology, the "core" site (Fig. 1,
boxed), which is conserved in mammalian C-type retroviral
enhancers (19). It is also found in the TCR y- and 5-chain
enhancers (15, 16), in the CD3 8- and E-chain enhancers (14,
15), and the polyoma virus enhancer (18). We have recently
purified proteins, CBFs, that bind to this site in retroviral
enhancers (25).
The ability of 8E2 and PE3 to bind to Ets proteins was
demonstrated by using recombinant Ets-1. When 32P-labeled
f3E2 or 8E3 oligonucleotide was added to baculovirus-
infected insect cell extracts containing recombinant chicken
Ets-1, a specifically retarded band was seen (Fig. 2A). The
retarded band was inhibited by an oligonucleotide corre-
sponding to the Ets-binding site described in the human
T-lymphotropic virus type 1 (HTLV-1) long terminal repeat
(22) but not with a mutated nonbinding version of this
oligonucleotide. The BE2 and PE3 bands were also cross-
inhibited by unlabeled f3E3 orBE2, respectively. The affinity
of the 83E2 and PE3 Ets-1-binding sites appeared to be
comparable with the HTLV-1 long terminal repeat Ets site.
Similar experiments with infected insect cell extracts con-
taining recombinant human Ets-2 showed that the ,BE2 and
,3E3 elements also bound to Ets-2 (data not shown).
The ability of BE2 to bind to CBF was also assessed by
gel-retardation analysis. Labeled PE2 was retarded by puri-
fied CBF, and the retarded band was inhibited by unlabeled
,BE2 and by a 3E2 oligonucleotide in which the Ets-binding
site had been mutated (fE2M1) (Fig. 2B). However, a
mutated BE2 oligonucleotide in which the core site was
disrupted (f3E2M2) failed to compete for binding. Unlabeled
Ml M2
rI1 I I
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FIG. 1. Sequence comparison of 8E2 and f3E3 elements. Se-
quences of PE2 and (BE3 footprinting regions are shown. Arrows
represent orientation (--, upper strand; +-, lower strand). The two
areas of homology between 13E2 and f3E3 are underlined and boxed.
Mutations in the SE2 and 8E3 sites used in functional assays are
shown.
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FIG. 2. Binding properties of fE2 and f3E3. (A) Labeled E2 or ,E3 was incubated in the presence ofbaculovirus-infected insect cell extracts
containing recombinant Ets-1 or in the presence of a control extract (lane c) containing no Ets protein. The retarded Ets-1 complex was inhibited
with the following unlabeled oligonucleotides: pBE2, PE3, HTLV-1 (H), HTLV-1M (M) (a mutant version of HTLV-1 that does not bind Ets
proteins). (B) Labeled (E2 was incubated with CBF purified from calf thymus. The retarded complex was inhibited with unlabeled BE2, mutants
13E2M1 and ,E2M2 (see Fig. 1), or 1E3.
18E3 completely inhibited binding of CBF by labeled 3E2,
showing that /3E3 also binds CBF (Fig. 2B).
The Ets-Binding Site Is Essential for Inducibility of fiE2. The
importance of the Ets- and CBF-binding motifs within PE2
for the activity and inducibility of the TCR, enhancer was
determined by mutation analysis. In Jurkat cells the basal
activity of the TCRP enhancer construct (3E2M1) in which
the Ets-binding site in f3E2 had been mutated was consis-
tently higher (1.2- to 2-fold) than that of unmutated KS7.8; in
contrast, the inducibility of 3E2M1 was only :40% that of
the wild-type enhancer (Table 3). The residual inducibility of
the PE2M1 construct was accounted for by the activity of
,BE3. Mutation of both the /3E2 and /E3 Ets-binding sites
(f3E2M1f3E3M1) decreased the basal activity and abolished
the PMA inducibility. Mutation of the fBE3 Ets-binding site
alone (f3E3M1) decreased both activity and inducibility ofthe
enhancer to levels similar to those seen when the entire PE3
region was deleted (A,3E3). A construct in which the Ets sites
within the /3E2 multimer were mutated (83E2M1x4) showed
no inducibility in Jurkat (data not shown).
In K-562 cells, mutation of the ,BE2 Ets-binding site dras-
tically reduced both basal activity and inducibility (Table 3).
Table 3. Effect on activity and inducibility of mutations and
deletions within the TCRI8 enhancer
J6 K-562
CAT Induci- CAT Induci-
Construct activity* bilityt activity* bilityt
KS7.8 5.25 13 7.41 5.9
APE2 2.40 2.5 0.21 1.8
AfE3 2.75 9.8 2.30 4.5
,BE2M1 7.65 5.6 0.40 1.3
f3E3M1 3.60 7.9 3.33 2.4
/3E2M1PE3M1 1.51 1.0 0.18 1.3
,BE2M2 3.20 14.5 0.15 9.3
pBLCAT2 0.09 0.8 0.10 0.8
*Activity in cpm x 10-3, normalized for luciferase activity.
tRatio of + PMA to - PMA.
Mutation of the (3E3 Ets site moderately reduced basal and
inducible activity. Mutation of both Ets sites effectively
abolished both basal and inducible activity.
Mutation of the 3' region of ,IE2 that abolishes binding of
CBF but not of Ets factors (8E2M2) reduced basal enhancer
activity in both Jurkat and K-562 cells (Table 3). However,
the inducibility of the TCRf3 enhancer was not decreased by
this mutation. Taken together, these data show that the
Ets-binding sites in PE2 and ,BE3 are important for PMA
inducibility, whereas the CBF-binding sites appear essential
only for full activity of the TCRB enhancer.
Coexpression of Ets-1 Represses TCRIJ Enhancer Activity.
To elucidate the functional consequences of the binding of
Ets-1 to the 3E2 and E3 regions, cotransfection experiments
were undertaken by using an expression plasmid encoding
the chicken equivalent of the major 55-kDa form of Ets-1
found in lymphoid cells (22). In both K-562 and Jurkat cells
Ets-1 expression repressed greatly the activity of KS7.8 and
,BE2x4 in the presence of PMA. Repression of basal activity
was also seen in the absence of PMA (Table 4).
The specificity of the repression of TCR(3 activity was
demonstrated by several criteria. (i) Coexpression of Ets-2
had little effect on activity of the TCR enhancer, although
Ets-1 and Ets-2 both transactivated the HTLV-1 enhancer in
T cells. (ii) Ets-1 expression did not affect activities of the
Moloney sarcoma virus long terminal repeat or the CD2
enhancer in T cells (data not shown).
Table 4. Effect of Ets-1 coexpression on activity of the TCR3
enhancer and the ,E2 multimer
CAT activity*
Reporter Expression J6 K-562
construct construct - PMA + PMA - PMA + PMA
KS7.8 Control 1.0 31.6 1.0 4.5
Ets-1 0.6 3.2 0.2 1.2
I3E2x4 Control 0 6.1 9.1 30.1
Ets-1 0 0.6 0.6 4.1
*Activity in cpm x 10-3, normalized for luciferase activity.
PE2
PE3
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DISCUSSION
A number of studies indicate that the transcription rate of the
TCRY gene varies during differentiation and'in mature T'cells
on T-cell activation. Trar scj-iption of TCR/3 genes is upreg-
ulated by protein kinase C activation (8), which- can be
mimicked with PMA (28). The basis for the inducibility of
human TCRf3 enhancer activity resides in a functional do-
main containing the E2- and E3-binding sites.
'3E2 and (3E3 each bind-to Ets-1 and Ets-2 and to the CBF
transcription factor. Mutational analysis reveals that the
integrnty of- Ets-binding sites is essential for, inducibility,
whereas the CBF-binding' site `is important only for basal
activity. Mutations within the CBF-binding site in the TCR6
enhancer also substantially decrease its activity (16). Re-
moval of the entire 83E2 element from the TCRB enhancer
severely reduces the phorbol ester response, suggesting that
synergistic interactions of proteins binding to ,BE2 and PE3
are required for optimal phorbol ester induction. Interest-
ingly, the Moloney virus enhancer also has a PMA-inducible
element that contains a binding site for CBF (TGTGGTAA)
and two Ets-binding sites (the leukemia virus factor b and c
sites) (refs. 25 and 29; Barbara Graves, personal communi-
cation). The importance of the Ets-binding sites within the
TCRP enhancer for its phorbol ester inducibility is consistent
with the observation that the activity of the stromelysin
promoter that contains an AP-1 site and two Ets-binding sites
is increased by PMA but that the PMA response does not
require the integrity of the AP-1 site (30, 31).
The observed repression by Ets-1 of TCRj3 enhancer
activity contrasts with its transactivation of other enhancers
(see, for example, ref. 22). This repression may, however, be
of physiological significance in modulation of the transcrip-
tional activity of the TCR"3 enhancer in T-cell. activation. It
has been postulated that Ets-1 is involved in maintaining T
cells in a quiescent state, whereas Ets-2 is required for
cellular activation'and proliferation (32). Thus, modulation of
the activity of the TCRI3 enhancer could be achieved by
varying the occupancy of the 13E2 and /E3 sites by Ets-1 by
competition for binding with an additional Ets protein. There
are several mechanisms by which the level of Ets-1 can be
varied in T cells, depending on the activation stimulus
received, including decreasing transcription of ets-) on ex-
posure to phorbol esters (32) and reducing the binding of
Ets-1 to DNA by calcium-dependent phosphorylation (33)
induced by mitogens or calcium ionophores. This latter
mechanism may operate on activation of quiescent T cells
that express a very high level of Ets-1 (33).
Ets-binding sites are present in enhancers of other T-cell-
specific genes including sites within the interleukin 2 enhancer
that mediate activation in response to phytohemagglutinin
stimulation and that bind the inducible nuclear factors NF-AT
and NF-IL-2B (34). Recently, the Elf-1 Ets-related factor has
been shown to bind to two sites within the interleukin 2
enhancer (35). Thus, it is possible that the Ets family of
transcription factors perform a general regulatory function
within genes that are transcriptionally up-regulated in T-cell
differentiation and activation. Variations in the precise re-
sponse of different genes during activation would depend on
the interaction ofdistinct Ets factors with other transcriptional
activators and coactivators. In this context, it is interesting to
note that Ets proteins have been implicated as components of
the signal-transduction pathway mediating the inducibility of
enhancers in response to serum growth factors, phorbol es-
ters, and nonnuclear oncogenes (31, 36-38).
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